Research Article
No access
Published Online: 22 July 2019

Long-Term Effectiveness of Continuous Subcutaneous Insulin Infusion in the Prevention of Hypoglycemia in Adults with Type 1 Diabetes

Publication: Diabetes Technology & Therapeutics
Volume 21, Issue Number 8

Abstract

Background: Reducing hyperglycemia while avoiding hypoglycemia is the key clinical goal in managing people with type 1 diabetes. Insulin delivery techniques and regimens are constantly evolving to achieve these goals. At present, use of multiple daily injections (MDI) is the standard of care, but there is increasing interest in continuous subcutaneous insulin infusion (CSII). There is a deficit of studies comparing long-term glycemic control and hypoglycemia outcomes between these therapeutic options.
Methods: This was a single-center, retrospective cohort study of adults with type 1 diabetes. Data were derived from electronic medical records and included demographic and clinical factors. Participants had all undergone intensive diabetes education, followed by CSII or continued MDI. The primary outcome was difference in hypoglycemia, defined as the percentage of self-monitoring blood glucose levels less than 3.9 mmol/L. Up to 10 years of follow-up data were available, between 2000 and 2016.
Results: There were 69 participants using CSII and 78 using MDI. Self-monitoring blood glucose data showed significantly less hypoglycemia with CSII by over 30%, occurring as early as the first year and sustained throughout the follow-up period (P < 0.001). This benefit of CSII on reducing hypoglycemia was independent of more frequent hypoglycemia and higher body weight at baseline, factors that were also independently associated with reduced hypoglycemia.
Conclusions: In selected adults with type 1 diabetes, long-term CSII can provide long-term clinically relevant and sustained reductions in hypoglycemia, particularly in those with greater initial risk of hypoglycemia and higher body weight, and improved glycemic control compared with MDI.

Get full access to this article

View all available purchase options and get full access to this article.

References

1. DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ 2002;325:746.
2. DeVries JH, Snoek FJ, Kostense PJ, et al. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 2002;25:2074–2080.
3. Kovatchev BP, Cox DJ, Gonder-Frederick LA, et al. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care 1998;21:1870–1875.
4. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271–286.
5. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993;91:819–828.
6. Parekh W, Hoskins N, Baker-Knight J, et al. The economic burden of insulin-related hypoglycemia in Spain. Diabetes Ther 2017;8:899–913.
7. Yeh HC, Brown TT, Maruthur N, Ranasinghe P, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med 2012;157:336–347.
8. Pickup JC, Sutton AJ. Severe hypoglycemia and glycemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765–774.
9. REPOSE Study Group TRS. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ 2017;356:j1285.
10. Rosenlund S, Hansen TW, Andersen S, Rossing P. Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study. Diabet Med 2015;32:1445–1452.
11. Speight J, Amiel SA, Bradley C, et al. Long-term biomedical and psychosocial outcomes following DAFNE (dose adjustment for normal eating) structured education to promote intensive insulin therapy in adults with sub-optimally controlled Type 1 diabetes. Diabetes Res Clin Pract 2010;89:22–29.
12. Bolli GB. Hypoglycemia unawareness. Diabetes Metab 1997; 23(Suppl 3):29–35.
13. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994;17:697–703.
14. Census of Population and Housing: Socio-Economic Indexes for Area (SEIFA) Australia, 2011 (Cat. No. 2033.0.55.001).

Information & Authors

Information

Published In

cover image Diabetes Technology & Therapeutics
Diabetes Technology & Therapeutics
Volume 21Issue Number 8August 2019
Pages: 423 - 429
PubMed: 31180239

History

Published in print: August 2019
Published online: 22 July 2019
Published ahead of print: 10 June 2019

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Julia C. Summers
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Clinical Diabetes, Baker Heart and Diabetes Institute, Melbourne, Australia.
Esther M. Briganti [email protected]
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Zachary A. Fitzgerald
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Clinical Diabetes, Baker Heart and Diabetes Institute, Melbourne, Australia.
Leo N.J. Lambers
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Clinical Diabetes, Baker Heart and Diabetes Institute, Melbourne, Australia.
Neale D. Cohen
Clinical Diabetes, Baker Heart and Diabetes Institute, Melbourne, Australia.

Notes

Address correspondence to: Esther M. Briganti, MBBS, MClinEpi, PhD, Department of Epidemiology and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne 3004, Australia [email protected]

Disclosure Statement

J.C.S., Z.A.F., and L.N.J.L.: No competing conflict of interests exists. E.M.B.: Honoraria: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and ApoPharma; educational grants: Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; travel funding: Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. N.D.C.: Honoraria: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Medtronic, MSD, Novo Nordisk, and Sanofi; educational grants: Medtronic, MSD, and Sanofi; travel funding: Abbott, Eli Lilly, MSD, Novo Nordisk, and Sanofi.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Figures

Tables

Media

Share

Share

Copy the content Link

Share on social media

Back to Top